Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 7-10 November 2016

  • Email
  • Help

News

11/11/2016

Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 7-10 November 2016

Nine medicines recommended for approval, including three biosimilars

The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) recommended nine medicines for approval at its November meeting.

The CHMP recommended granting a marketing authorisation for Afstyla (lonoctocog alfa) for the prevention and treatment of bleeding in patients with haemophilia A.

Vemlidy (tenofovir alafenamide) received a positive opinion from the CHMP for the treatment of chronic hepatitis B.

Fiasp (insulin aspart) was recommended for approval by the CHMP for the treatment of diabetes.

Suliqua (insulin glargine / lixisenatide) was recommended for approval for the treatment of type 2 diabetes.

Three biosimilar medicines were recommended for approval by the Committee: Lusduna (insulin glargine) for the treatment of diabetes, and Movymia and Terrosa (both containing teriparatide) for the treatment of osteoporosis. A biosimilar medicine is a biological medicine that is similar to another biological medicine that is already authorised for use.

Two generic medicines were recommended for approval: Darunavir Mylan (darunavir) for the treatment of human immunodeficiency virus (HIV-1) infection and Tadalafil Generics (tadalafil) for the treatment of pulmonary arterial hypertension.

Five recommendations on extensions of therapeutic indications

The Committee recommended extensions of indications for Arzerra, Caprelsa, Humira, Nimenrix and Vimpat.

Translarna: renewal of conditional marketing authorisation

The CHMP completed its scientific assessment of the annual renewal of the conditional marketing authorisation for Translarna (ataluren) and recommended that the conditional marketing authorisation be renewed.

As part of the CHMP assessment, the Committee reviewed all available data, including the results of a study performed by the marketing authorisation holder as a requirement of the conditional marketing authorisation after initial approval. Although the data available to date continue to indicate that Translarna slows the progression of the disease and there are no major safety concerns, the Committee considered that further comprehensive data are still needed to fully confirm that the benefit-risk balance of the medicine is positive.

The CHMP has therefore requested that the marketing authorisation holder for Translarna conducts a new 18-month randomised, placebo-controlled study in patients with Duchenne muscular dystrophy, followed by an 18-month period where all patients will be switched to Translarna. The study results are expected to be available in the first quarter of 2021.

Translarna is used to treat patients aged five years and older with Duchenne muscular dystrophy, a serious and rare condition for which no authorised treatments are currently available. The medicine is intended for use in patients who are able to walk and whose disease is caused by a specific genetic defect (called a ‘nonsense mutation’) in the gene for the muscle protein dystrophin.

Conditional approval allows EMA to recommend a medicine for marketing authorisation where the benefit to public health of its immediate availability on the market outweighs the risk inherent in the fact that additional data are still required. These medicines are subject to specific post-authorisation obligations that aim to generate comprehensive data on the medicine. Conditional marketing authorisations are valid for one year and can be renewed or converted to a standard five-year marketing authorisation when the additional data generated confirm that the benefit-risk balance of the medicine is positive.

The assessment report on the renewal of the conditional marketing authorisation for Translarna will be published after the European Commission issues its decision on the renewal.

Agenda and minutes

The agenda of the November 2016 CHMP meeting is published on EMA’s website. Minutes of the October 2016 CHMP meeting will be published next week.

CHMP statistics

Key figures from the November 2016 CHMP meeting are represented in the graphic below.

More information on this, and all other outcomes of the CHMP’s November 2016 meeting, is available in the grid below.

CHMP_highlights_November_2016

Download image in PDF format


Positive recommendations on new medicines

Name of medicineAfstyla
International non-proprietary name (INN)lonoctocog alfa
Marketing-authorisation applicantCSL Behring GmbH
Therapeutic indicationTreatment and prophylaxis of bleeding in patients with haemophilia A
More informationSummary of opinion for Afstyla

 

Name of medicineFiasp
International non-proprietary name (INN)insulin aspart
Marketing-authorisation applicantNovo Nordisk A/S
Therapeutic indicationTreatment of diabetes
More informationSummary of opinion for Fiasp

 

Name of medicineSuliqua
International non-proprietary name (INN)insulin glargine / lixisenatide
Marketing-authorisation applicantSanofi-aventis groupe
Therapeutic indicationTreatment of type 2 diabetes
More informationSummary of opinion for Suliqua

 

Name of medicineVemlidy
INNtenofovir alafenamide
Marketing-authorisation applicantGilead Sciences International Ltd
Therapeutic indicationTreatment of chronic hepatitis B
More informationSummary of opinion for Vemlidy

 

Positive recommendations on new generic medicines

Name of medicineDarunavir Mylan
INNdarunavir
Marketing-authorisation applicantMYLAN S.A.S
Therapeutic indicationTreatment of human immunodeficiency virus (HIV-1) infection
More informationSummary of opinion for Darunavir Mylan

  

Name of medicineTadalafil Generics
INNtadalafil
Marketing-authorisation applicantMYLAN S.A.S
Therapeutic indicationTreatment of pulmonary arterial hypertension
More informationSummary of opinion for Tadalafil Generics

 

Positive recommendations on new biosimilar medicines

Name of medicineLusduna
INNinsulin glargine 
Marketing-authorisation applicantMerck Sharp & Dohme Limited
Therapeutic indicationTreatment of diabetes
More informationSummary of opinion for Lusduna

 

Name of medicineMovymia
INNteriparatide
Marketing-authorisation applicantSTADA Arzneimittel AG
Therapeutic indicationTreatment of osteoporosis
More informationSummary of opinion for Movymia

 

Name of medicineTerrosa
INNteriparatide
Marketing-authorisation applicantGedeon Richter Plc.
Therapeutic indicationTreatment of osteoporosis
More informationSummary of opinion for Terrosa

 

Positive recommendations on extensions of therapeutic indications

Name of medicineArzerra
INNofatumumab
Marketing-authorisation holderNovartis Europharm Ltd
More informationSummary of opinion for Arzerra

  

Name of medicineCaprelsa
INNvandetanib
Marketing-authorisation holderGenzyme Europe BV
More informationSummary of opinion for Caprelsa

  

Name of medicineHumira
INNadalimumab
Marketing-authorisation holderAbbVie Ltd
More informationSummary of opinion for Humira

  

Name of medicineNimenrix
INNmeningococcal group A, C, W135 and Y conjugate vaccine
Marketing-authorisation holderPfizer Limited
More informationSummary of opinion for Nimenrix

  

Name of medicineVimpat
INNlacosamide
Marketing-authorisation holderUCB Pharma S.A.
More informationSummary of opinion for Vimpat

 

Other opinion

Name of medicineRuconest
INNconestat alfa
Marketing-authorisation holderPharming Group N.V
More informationSummary of opinion for Ruconest

 

Other updates

Recommendations on eligibility to PRIME scheme
Scientific advice and protocol assistance
Start of community reviews
Overview of (invented) names reviewed in October 2016 by the Name Review Group (NRG)

How helpful is this page?

Average rating:

 Based on 9 ratings

Add your rating:

See all ratings
1 ratings
2 ratings
0 ratings
3 ratings
3 ratings
    

Tell us more

Related content

Please note that not all documents associated with this page are published at the same time. This page is updated with new documents as soon as they become available. Therefore, users are asked to check the page regularly.

Contact point:

Tel. +44 (0)20 3660 8427
E-mail: press@ema.europa.eu
Follow us on Twitter @EMA_News